In addition, the potential elevation of MHC class I on tumor cells by PolyICPEI (34) prior to cell death by DaRT may increase the probability to present yet non-presented tumor antigens in the context of MHC class I. Thus, it can be speculated that PolyICPEI-treated, and alpha-radiation-killed, tumor cells may release such MHC class I-antigen complexes, which can be picked up by DCs that in turn present them to CD8+ T cells and help to expand the number of clones recognizing tumor antigens. The gene discussed is CD8A; the disease is neoplasm.